Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

FDA Clears Prescription Mobile Software Application to Treat Opioid Use Disorder

By Mike Botta | December 11, 2018

Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., a provider of prescription digital therapeutics, announced that the U.S. Food and Drug Administration has granted clearance for reSET-O, a 12-week prescription mobile software application intended to increase retention for patients with opioid use disorder.

The outpatient treatment is designed to provide cognitive behavioral therapy as an adjunct to outpatient treatment that includes transmucosal buprenorphine (medication-assisted-treatment) and contingency management. It’s for patients 18 years or older who are currently under the supervision of a clinician and is indicated as prescription-only.

“Digital technologies and data science have incredible potential to unlock the next chapter of medical innovation and to help individuals finally take control of their own health in a meaningful way,” said Richard Francis, Sandoz CEO. “New digital therapeutics such as reSET-O also have the potential to fundamentally change how patients interact with their therapies and thus improve patient outcomes.”

Under the terms of a commercial deal announced in April, Sandoz will lead marketing and commercialization of reSET-O and reSET, Pear’s photodynamic therapy for the treatment of substance use disorder. Sandoz launched reSET in November 2018 and plans to soon launch reSET-O in the U.S. 

The reSET-O photodynamic therapy is modeled on the community reinforcement approach and engineered to deliver cognitive behavioral therapy. It delivers therapy as a series of interactive lessons, each comprised of a cognitive behavioral therapy component and skill-building exercises.

Content is delivered primarily via text or audio, and may include videos, animations, and graphics.

More than 80 percent of patients with opioid use disorder do not receive or seek out carei and only 13 percent of outpatient facilities in the U.S. offer medication-assisted-treatment, such as buprenorphineii.

High attrition and relapse rates represent a significant problem and retention in treatment is a well-established indicator of successful outcomesiii.
____________________________________________________________

References:

i Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings (NSDUH Series H-48, HHS Publication No. SMA 14-4863). 2014:1-184. https://store.samhsa.gov/shin/content/SMA16-4892PG/SMA16-4892PG.pdf

ii Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS): 2013. Data on Substance Abuse Treatment Facilities. BHSIS Series S-73, HHS Publication No. (SMA) 14-4890. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014.

iii Weisner C et al. Short-term alcohol and drug treatment outcomes predict long-term outcome. Drug and Alcohol Dependence. 2003. 71: 281-294.

(Sources: Sandoz Inc. and Pear Therapeutics, Inc.)

Related Articles Read More >

From solar system simulations to SaaS savings, how Codeium’s AI agent empowers non-coders and scientists alike
Aardvark AI forecasts rival supercomputer simulations while using over 99.9% less compute
Quantum Brilliance, Pawsey integrate room-temp quantum with HPC on NVIDIA GH200
Frontier supercomputer reveals new detail in nuclear structure
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE